Ácido tranexámico en cirugía ortopédica / Tranexamic acid in orthopedic surgery

El sangrado perioperatorio en ocasiones conduce a transfusiones sanguíneas no exentas de complicaciones y riesgos, con un alto gasto sanitario. Entre otros métodos de prevención, el tratamiento con ácido tranexámico (TXA) ha mostrado ser efectivo en la disminución de las pérdidas sanguíneas quirúrgicas y especialmente en el postoperatorio inmediato. Al respecto, los estudios que lo han evaluado en cirugía ortopédica muestran su eficacia y seguridad, administrado por vía tanto intravenosa como intraarticular. Las dosis habituales por vía intravenosa evaluadas oscilan entre 10 y 20 mg/kg, o en dosis fijas de 1 a 2 g, mientras por vía intraarticular varía entre 250 mg y 3 g. El TXA como antifibrinolítico tiene un potencial efecto trombótico y está contraindicado en aquellos pacientes con riesgo o antecedentes de trombosis. Su administración por vía tópica podría ser más segura aunque se precisan estudios que lo confirmen (AU)

Perioperative bleeding may require blood transfusions, which are sometimes not without complications and risks, with the subsequent increase in health care costs. Among other prevention methods, treatment with tranexamic acid (ATX) has shown to be effective in reducing surgical blood loss, especially in the immediate postoperative period. In this regard, studies evaluating ATX in orthopedic surgery show that it is effective and safe when administered intravenously or intra-articularly. The usual evaluated intravenous doses range between 10 mg/Kg and 20 mg/kg or a fixed dose of 1 g to 2 g; while intra-articularly, it varies between 250 mg and 3 g. ATX, as an anti-fibrinolytic has a potential thrombotic effect, thus it is contraindicated in those patients at risk or with a history of thrombosis. Its topical administration may be safer, but studies are needed to confirm this (AU)

Análise dos custos de pacientes internados na Santa Casa Misericórdia de Campo Grande, tratados com e sem auxílio de oxigenoterapia hiperbárica / Cost analysis in patients admitted to the Santa Casa Misericórdia de Campo Grande, treated with and without the aid of hyperbaric oxygen therapy

INTRODUÇÃO: As queimaduras estão entre as principais causas externas de morte no Brasil, geram enormes gastos financeiros e são responsáveis por sequelas físicas, psicológicas e sociais. O Objetivo deste estudo foi comparar os dois grupos de pacientes queimados com e sem tratamento coadjuvante com Oxigenoterapia Hiperbárica, assim como, realizar uma análise dos custos. MÉTODOS: Foi realizado estudo retrospectivo, período de 2011 a 2013, selecionando, 20 pacientes com queimaduras moderadas e graves, internados na Santa Casa de Misericórdia de Campo Grande, tratados com auxílio de OHB (grupo I) e 22 pacientes sem auxílio de OHB (grupo II). RESULTADOS: A maioria dos pacientes pertencia ao sexo masculino, 24 pacientes (57,1%). O agente etiológico mais frequente nos dois grupos foi produtos inflamáveis com 56,6% dos casos. A idade média do grupo I foi de 26,6 e a do grupo II 23,3, predominando a faixa etária entre 13 e 35 anos 50,4% dos pacientes. Custo médio final por paciente do Grupo I foi R$17.292,00, e grupo II R$25.360 (p=0,028). CONCLUSÃO: Concluímos que, no nosso serviço, o grupo de pacientes com queimaduras moderadas e graves tratados com auxílio da Oxigenioterapia Hiperbárica teve um menor número de procedimentos cirúrgicos, como enxertos e desbridamento, e menor tempo de internação, levando a uma economia importante dos gastos hospitalares.

INTRODUCTION: Burns are among the leading external causes of death in Brazil, generating huge costs and having physical, psychological, and social consequences. The objective of this study was to compare two groups of burn patients, i.e., those with and those without adjuvant treatment with hyperbaric oxygen (HBO) therapy and to perform a cost analysis. METHODS: A retrospective study was carried out between 2011 and 2013, comparing 20 patients with moderate to severe burns who were hospitalized at the Santa Casa de Misericórdia de Campo Grande and treated with HBO (group I) and 22 patients treated without HBO (group II). RESULTS: Most of the patients, i.e., 24 (57.1%), were male. Flammable product was the most frequent etiologic agent in both groups, accounting for 56.6% of the burn cases. The average age of group I patients was of 26.6 years and that of group II was of 23.3 years, with a prevalence (50.4%) of those aged between 13 and 35 years. The average final cost per patient was R$17,292.00 for group I and R$25,360 for group II (p = 0.028). CONCLUSION: We conclude that, in our service, patients presenting moderate and severe burns and treated with HBO therapy underwent a lower number of surgical procedures, e.g., grafts and debridement that allowed reduced hospitalization time and led to significant savings in hospital costs.

Pediatric hospitalist systems versus traditional models of care: effect on quality and cost outcomes.

BACKGROUND: Pediatric hospitalist systems are increasing in popularity, but data regarding the effects of hospitalist systems on the quality of care has been sparse, in part because rigorous metrics for analysis have not yet been established. We conducted a literature review of studies comparing the performance of pediatric hospitalists and traditional attendings. OBJECTIVE: To determine the effect of pediatric hospitalists on quality and outcome metrics such as length of stay, cost, patient satisfaction, mortality, readmission rates, and use of evidence-based medicine during care. RESULTS: A Medline literature search identified 11 studies that met criteria for inclusion. Five previously reviewed studies reported lengths of stay between 6% and 14% shorter for hospitalists. Five of the new studies evaluated lengths of stay, with 1 showing significantly lower length of stay and cost for a faculty model, 1 showing lower length of stay for hospitalists for all conditions, 1 for certain conditions only, and 2 showing no statistical difference. Six studies reported on readmission rate, with 4 showing no difference, 1 showing decreased readmissions for hospitalists, and 1 showing decreased readmissions for a traditional faculty service. Hospitalists self-report higher use of evidence-based guidelines. Few differences in patient satisfaction were reported. Mortality on the pediatrics wards is rare, and no studies were adequately powered to evaluate mortality rate. CONCLUSION: Hospitalists can improve the quality and efficiency of inpatient care in the pediatric population, but the effect is not universal, and mechanisms underlying demonstrated improvements are poorly understood. We propose 4 components to improve quality and value in hospital medicine systems: investment in comparative effectiveness research involving delivery system interventions, development and implementation of pediatric quality measures, better understanding of improvement mechanisms for hospital medicine systems, and increased focus on quality and value delivered by hospital medicine groups and individuals.

Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.

This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals--Germany, the Netherlands, and New Zealand--and examines their effects on the availability of new drugs, reimbursement levels, manufacturer prices, and out-of-pocket surcharges to patients. RP for pharmaceuticals is not simply analogous to a defined contribution approach to subsidizing insurance coverage. Although a major purpose of RP is to stimulate competition, theory suggests that the achievement of this goal is unlikely, and this is confirmed by the empirical evidence. Other effects of RP differ across countries in predictable ways, reflecting each country's system design and other cost-control policies. New Zealand's RP system has reduced reimbursement and limited the availability of new drugs, particularly more expensive drugs. Compared to these three countries, if RP were applied in the United States, it would likely have a more negative effect on prices of onpatent products because of the more competitive U.S. generic market, and on research and development (R&D) and the future supply of new drugs, because of the much larger U.S. share of global pharmaceutical sales.